| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. (REGN) has 19 insiders with recent SEC Form 4 filings, including 0 buys and 37 sells. REGN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Pres | 310.5K | $189.36M | - | |
| CEO | 214.5K | $130.85M | - | |
| VP | 47.8K | $29.18M | - | |
| VP | 29.5K | $18.00M | - | |
| VP | 21.7K | $13.22M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2022 | Murphy Andrew J54 | EVP Research | Sale+OE | 3,540 | $629.34 | $2,227,850.52 | -0.5% | +3.9% | +19.4% | |
| Feb 1, 2022 | Ryan Arthur F54 | Director | Sell | 100 | $607.14 | $60,714.26 | - | +6.3% | +23.6% | |
| Feb 1, 2022 | McCourt Marion55 | EVP Commercial | Sale+OE | 1,000 | $607.46 | $607,460.00 | -4.8% | +6.3% | +23.6% | |
| Jan 3, 2022 | Ryan Arthur F54 | Director | Sell | 100 | $624.95 | $62,494.78 | - | +11.4% | +14.9% | |
| Jan 3, 2022 | McCourt Marion55 | EVP Commercial | Sale+OE | 1,000 | $625.00 | $625,000.00 | -4.8% | +11.4% | +14.9% | |
| Dec 13, 2021 | McCourt Marion55 | EVP Commercial | Sell | 344 | $653.12 | $224,673.28 | -1.7% | -0.6% | +13.2% | |
| Dec 13, 2021 | Landry Robert E52 | EVP Finance CFO | Sale+OE | 116 | $662.50 | $76,850.00 | -0.4% | -0.6% | +13.2% | |
| Dec 10, 2021 | Murphy Andrew J54 | EVP Research | Sale+OE | 399 | $657.61 | $262,386.39 | -0.6% | -5.8% | +12.0% | |
| Dec 10, 2021 | Landry Robert E52 | EVP Finance CFO | Sale+OE | 2 | $656.46 | $1,312.92 | - | -5.8% | +12.0% |